Search research articles
Contact Us
Filters
Showing results (1-10 of 179) with videos related to
Page
of 18
Sort By:
JCO Precision Oncology
|
February 9, 2022
Tumor Suppressor Tolerance: Reversion Mutations in BRCA1 and BRCA2 and Resistance to PARP Inhibitors and Platinum
Shridar Ganesan
JCO Precision Oncology
|
December 14, 2023
Treating Early and Often: Targeted Therapeutics in the Adjuvant Setting
Shridar Ganesan
The Journal of Clinical Investigation
|
August 15, 2022
Breaking satellite silence: human satellite II RNA expression in ovarian cancer
Shridar Ganesan
Science Signaling
|
March 31, 2011
MYC, PARP1, and chemoresistance: BIN there, done that?
Shridar Ganesan
Journal of Molecular Cell Biology
|
February 1, 2011
BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability
Amal Aly, Shridar Ganesan
JCO Precision Oncology
|
January 20, 2022
Poly (ADP-Ribose) Polymerase Inhibitor Activity in Prostate Cancers Harboring Mutations in DNA Repair Genes: Who Benefits?
Shridar Ganesan, Judy Garber
Frontiers in Genetics
|
August 9, 2021
Genomic and Immunologic Correlates of Indoleamine 2,3-Dioxygenase Pathway Expression in Cancer
Anshuman Panda, Shridar Ganesan
Current Opinion in Obstetrics & Gynecology
|
December 19, 2013
Triple-negative breast cancer: molecular subtypes and targeted therapy
Kim M Hirshfield, Shridar Ganesan
Cancer
|
November 12, 2025
Microsatellite instability: Advances in diagnosis
Patrick M Boland, Shridar Ganesan
Nature Cancer
|
April 26, 2021
Emerging strategies for treating metastasis
Mark Esposito, Shridar Ganesan, Yibin Kang
Page
of 18
Search research articles
Search
Showing results (1-10 of 179) with videos related to
Sort By:
Page
of 18
JCO Precision Oncology
|
February 9, 2022
Tumor Suppressor Tolerance: Reversion Mutations in BRCA1 and BRCA2 and Resistance to PARP Inhibitors and Platinum
Shridar Ganesan
JCO Precision Oncology
|
December 14, 2023
Treating Early and Often: Targeted Therapeutics in the Adjuvant Setting
Shridar Ganesan
The Journal of Clinical Investigation
|
August 15, 2022
Breaking satellite silence: human satellite II RNA expression in ovarian cancer
Shridar Ganesan
Science Signaling
|
March 31, 2011
MYC, PARP1, and chemoresistance: BIN there, done that?
Shridar Ganesan
Journal of Molecular Cell Biology
|
February 1, 2011
BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability
Amal Aly, Shridar Ganesan
JCO Precision Oncology
|
January 20, 2022
Poly (ADP-Ribose) Polymerase Inhibitor Activity in Prostate Cancers Harboring Mutations in DNA Repair Genes: Who Benefits?
Shridar Ganesan, Judy Garber
Frontiers in Genetics
|
August 9, 2021
Genomic and Immunologic Correlates of Indoleamine 2,3-Dioxygenase Pathway Expression in Cancer
Anshuman Panda, Shridar Ganesan
Current Opinion in Obstetrics & Gynecology
|
December 19, 2013
Triple-negative breast cancer: molecular subtypes and targeted therapy
Kim M Hirshfield, Shridar Ganesan
Cancer
|
November 12, 2025
Microsatellite instability: Advances in diagnosis
Patrick M Boland, Shridar Ganesan
Nature Cancer
|
April 26, 2021
Emerging strategies for treating metastasis
Mark Esposito, Shridar Ganesan, Yibin Kang
Page
of 18